1. Home
  2. BXC vs CTNM Comparison

BXC vs CTNM Comparison

Compare BXC & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bluelinx Holdings Inc.

BXC

Bluelinx Holdings Inc.

HOLD

Current Price

$56.09

Market Cap

587.2M

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$12.87

Market Cap

480.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BXC
CTNM
Founded
2004
2009
Country
United States
United States
Employees
1700
51
Industry
Wholesale Distributors
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
587.2M
480.5M
IPO Year
2004
2024

Fundamental Metrics

Financial Performance
Metric
BXC
CTNM
Price
$56.09
$12.87
Analyst Decision
Strong Buy
Buy
Analyst Count
3
4
Target Price
$86.00
$19.00
AVG Volume (30 Days)
93.6K
315.0K
Earning Date
04-28-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.46
EPS
0.02
N/A
Revenue
N/A
N/A
Revenue This Year
$5.04
N/A
Revenue Next Year
$5.09
N/A
P/E Ratio
$2,801.50
N/A
Revenue Growth
N/A
N/A
52 Week Low
$44.78
$3.35
52 Week High
$88.30
$16.33

Technical Indicators

Market Signals
Indicator
BXC
CTNM
Relative Strength Index (RSI) 51.73 45.42
Support Level $52.71 $11.54
Resistance Level $66.64 $13.18
Average True Range (ATR) 2.44 0.91
MACD 1.21 0.02
Stochastic Oscillator 87.21 41.38

Price Performance

Historical Comparison
BXC
CTNM

About BXC Bluelinx Holdings Inc.

BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: